Miejsce i rola rosuwastatyny w terapii hipolipemizującej Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2011
Słowa kluczowe:
cholesterol, leczenie hipolipemizujące, statyny, rosuwastatyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroby układu sercowo-naczyniowego pozostają główną przyczyną zgonów w krajach uprzemysłowionych. Ich rozwojowi sprzyja wysokie stężenie cholesterolu, ważnego, modyfikowalnego czynnika ryzyka chorób układu krążenia. Inhibitory enzymu 3-hydroksy-3-metyloglutarylo-koenzymu A (HMG-CoA), czyli statyny, są powszechnie stosowane w leczeniu zaburzeń lipidowych. Wyniki prowadzonych z randomizacją, kontrolowanych badań wskazują, że redukcja stężenia cholesterolu podczas stosowania statyn związana jest z istotnym ograniczeniem ryzyka sercowo-naczyniowego. Nowa statyna, rosuwastatyna, charakteryzuje się silnym działaniem hipolipemizującym, większym niż inne statyny. Należy podkreślić, że lek ma wysoki profil bezpieczeństwa i bardzo dobrą tolerancję. Wyniki coraz większej liczby badań pokazują, że rosuwastatyna hamuje postęp miażdżycy i zmniejsza ryzyko sercowo-naczyniowe, zwłaszcza u chorych w prewencji pierwotnej. Podczas badań u chorych z niewydolnością serca i nerek rosuwastatyna skutecznie obniżała stężenie cholesterolu, ale nie obserwowano jednocześnie redukcji epizodów sercowo-naczyniowych. Konieczne są dalsze badania określające miejsce rosuwastatyny w terapii farmakologicznej pacjentów z chorobami układu krążenia.
Pobrania
Dane pobrania nie są jeszcze dostepne
##plugins.themes.bootstrap3.article.details##
Jak cytować
Sobczyńska, M., & Lewandowski , J. (2011). Miejsce i rola rosuwastatyny w terapii hipolipemizującej . Kardiologia W Praktyce, 5(1), 9-17. Pobrano z https://journalsmededu.pl/index.php/kwp/article/view/1612
Numer
Dział
Artykuły
Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa – Użycie niekomercyjne – Bez utworów zależnych 4.0 Międzynarodowe.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
Bibliografia
1. Ezzati M., Lopez A.D., Rodgers A., Vander Hoorn S., Murray C.J.L.: Selected major risk factors and global and regional burden of disease. Lancet 2002, 360: 1347-60.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143-3421.
3. Pająk A., Wiercińska E., Polakowska M., Kozakiewicz K., Kaczmarczyk-Chałas K., Tykarski A., Gałdzik K., Zdrojewski T.: Rozpowszechnienie dyslipidemii u mężczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiologia Polska 2005, 63 (supl. 4): 1-6.
4. Czwarta Wspólna Grupa Robocza Europejskiego Towarzystwa Kardiologicznego i innych towarzystw do spraw prewencji chorób sercowo-naczyniowych w praktyce klinicznej. Europejskie wytyczne dotyczące prewencji chorób sercowo-naczyniowych w praktyce klinicznej – wersja skrócona. Kardiologia Polska 2008, 66 (supl. 1): 4.
5. Endo A.: The discovery and development of HMG-CoA reductase inhibitors. Atherosclerosis 2004, 5 (Suppl.): 67-80.
6. Vaughan C.I., Murphy M.B., Buckley B.M.: Statins do more than just lower cholesterol. Lancet 1996, 348: 1079-82.
7. Todd P.A., Goa K.L.: Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990, 40: 583-607.
8. Goldstein J.I., Brown M.S.: Regulation of the mevalonate pathway. Nature 1990, 343: 425-430.
9. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 1998, 18: 1671-1678.
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S.: Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998, 138: 271-279.
11. Joukhadar C., Klein N., Prinz M. et al.: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb. Haemost. 2001, 85: 47-51.
12. Konsensus Grupy Roboczej Polskiego Forum Profilaktyki ds. Wytycznych dotyczący farmakoterapii prewencyjnej. Forum Profilaktyki 2010, 2(10).
13. Wilt T.J., Bloomfield H.E., MacDonald R. et al.: Effectiveness of statin therapy in adults with coronary heart disease. Arch. Int. Med. 2004, 164: 1427-36.
14. Downs J.R., Clearfield M., Weis S. et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615-22.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
16. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333: 1301-1307.
17. Briel M., Schwartz G.G., Thompson P.L. et al.: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006, 295: 2046-56.
18. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G. et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335: 1001-1009.
19. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359: 1379-87.
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389.
21. Olsson A.G., Schwartz G.G., Szarek M. et al.: High-density lipoprotein,but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart J. 2005, 26(9): 890-6.
22. Cannon C., Braunwald E., McCabe C. et al.: Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE IT-TIMI 22). New Engl. J. Med. 2004: 350 [online: April 8, 2004].
23. Athyros V.G., Papageorgiou A.A., Mercouris B.R. et al.: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease evaluation (GREACE) study. Curr. Med. Res. Opin. 2002, 18: 220-228.
24. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-1158.
25. Shepherd J., Blauw G.J., Murphy M.B. et al.; PROSPER study group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360: 1623-1630.
26. Amarenco P., Labreuche J., Lavallee P. et al.: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35: 2902-9.
27. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364: 685-696.
28. Opolski G., Filipiak K.J.: Prewencja wtórna zawału serca w warunkach podstawowej opieki zdrowotnej w Polsce – wybrane wyniki programu POLKARD-SPOK. Kardiol. Pol. 2006, 64(Supl. 3): 198-209.
29. Bolego C., Poli A., CignarelIa A. et al.: Novel statins: pharmacological and clinical results. Cardiovasc Drugs Ther. 2002, 16: 251-7.
30. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology 2004, 19: 117-125.
31. Jones P.H., Davidson M.H., Stein E.H.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 2003, 91: 152-60.
32. Brewer H.B.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003, 92(Suppl.): 23K-29K.
33. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359: 2195-207.
34. Kjekshus J., Dunselman P., Blideskog M. et al.: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail. 2005, 7: 1059-69.
35. Crouse J.R. 3rd, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297: 1344-53.
36. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295: 1556-65.
37. Fellström B.C., Jardine A.G., Schmieder R.E.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009, 360: 1395-407.
38. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; 2010 June 27, Munich, Germany.
39. Wanner C., Krane V., Marz W.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353: 238-48.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106: 3143-3421.
3. Pająk A., Wiercińska E., Polakowska M., Kozakiewicz K., Kaczmarczyk-Chałas K., Tykarski A., Gałdzik K., Zdrojewski T.: Rozpowszechnienie dyslipidemii u mężczyzn i kobiet w wieku 20–74 lat w Polsce. Wyniki programu WOBASZ. Kardiologia Polska 2005, 63 (supl. 4): 1-6.
4. Czwarta Wspólna Grupa Robocza Europejskiego Towarzystwa Kardiologicznego i innych towarzystw do spraw prewencji chorób sercowo-naczyniowych w praktyce klinicznej. Europejskie wytyczne dotyczące prewencji chorób sercowo-naczyniowych w praktyce klinicznej – wersja skrócona. Kardiologia Polska 2008, 66 (supl. 1): 4.
5. Endo A.: The discovery and development of HMG-CoA reductase inhibitors. Atherosclerosis 2004, 5 (Suppl.): 67-80.
6. Vaughan C.I., Murphy M.B., Buckley B.M.: Statins do more than just lower cholesterol. Lancet 1996, 348: 1079-82.
7. Todd P.A., Goa K.L.: Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990, 40: 583-607.
8. Goldstein J.I., Brown M.S.: Regulation of the mevalonate pathway. Nature 1990, 343: 425-430.
9. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., Bernini F.: HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler. Thromb. Vasc. Biol. 1998, 18: 1671-1678.
10. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S.: Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation. Atherosclerosis 1998, 138: 271-279.
11. Joukhadar C., Klein N., Prinz M. et al.: Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb. Haemost. 2001, 85: 47-51.
12. Konsensus Grupy Roboczej Polskiego Forum Profilaktyki ds. Wytycznych dotyczący farmakoterapii prewencyjnej. Forum Profilaktyki 2010, 2(10).
13. Wilt T.J., Bloomfield H.E., MacDonald R. et al.: Effectiveness of statin therapy in adults with coronary heart disease. Arch. Int. Med. 2004, 164: 1427-36.
14. Downs J.R., Clearfield M., Weis S. et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998, 279: 1615-22.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360: 7-22.
16. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W. et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Engl. J. Med. 1995, 333: 1301-1307.
17. Briel M., Schwartz G.G., Thompson P.L. et al.: Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA 2006, 295: 2046-56.
18. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G. et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N. Engl. J. Med. 1996, 335: 1001-1009.
19. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002, 359: 1379-87.
20. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-1389.
21. Olsson A.G., Schwartz G.G., Szarek M. et al.: High-density lipoprotein,but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur. Heart J. 2005, 26(9): 890-6.
22. Cannon C., Braunwald E., McCabe C. et al.: Comparison of Intensive and Moderate Lipid Lowering with Statins after Acute Coronary Syndromes (PROVE IT-TIMI 22). New Engl. J. Med. 2004: 350 [online: April 8, 2004].
23. Athyros V.G., Papageorgiou A.A., Mercouris B.R. et al.: Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease evaluation (GREACE) study. Curr. Med. Res. Opin. 2002, 18: 220-228.
24. Sever P.S., Dahlof B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003, 361: 1149-1158.
25. Shepherd J., Blauw G.J., Murphy M.B. et al.; PROSPER study group: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360: 1623-1630.
26. Amarenco P., Labreuche J., Lavallee P. et al.: Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004, 35: 2902-9.
27. Colhoun H.M., Betteridge D.J., Durrington P.N. et al.: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364: 685-696.
28. Opolski G., Filipiak K.J.: Prewencja wtórna zawału serca w warunkach podstawowej opieki zdrowotnej w Polsce – wybrane wyniki programu POLKARD-SPOK. Kardiol. Pol. 2006, 64(Supl. 3): 198-209.
29. Bolego C., Poli A., CignarelIa A. et al.: Novel statins: pharmacological and clinical results. Cardiovasc Drugs Ther. 2002, 16: 251-7.
30. Schachter M.: Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundamental & Clinical Pharmacology 2004, 19: 117-125.
31. Jones P.H., Davidson M.H., Stein E.H.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR Trial). Am. J. Cardiol. 2003, 91: 152-60.
32. Brewer H.B.: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol. 2003, 92(Suppl.): 23K-29K.
33. Ridker P.M., Danielson E., Fonseca F.A. et al.: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008, 359: 2195-207.
34. Kjekshus J., Dunselman P., Blideskog M. et al.: A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail. 2005, 7: 1059-69.
35. Crouse J.R. 3rd, Raichlen J.S., Riley W.A. et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297: 1344-53.
36. Nissen S.E., Nicholls S.J., Sipahi I. et al.: Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295: 1556-65.
37. Fellström B.C., Jardine A.G., Schmieder R.E.: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N. Engl. J. Med. 2009, 360: 1395-407.
38. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; 2010 June 27, Munich, Germany.
39. Wanner C., Krane V., Marz W.: Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 2005, 353: 238-48.